SHJBF.US Shanghai Junshi Biosciences Co. Ltd

Healthcare Biotechnology USA Stocks
13.21 USD
Close of Nov 18, 2026
2.99 4.23
Market cap
USD 3.44B
P/E
-
P/B
3.84x
ROE
-3.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SHJBF.US undervalued?

Graham number

The Graham number of Shanghai Junshi Biosciences Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Shanghai Junshi Biosciences Co. Ltd fundamental analysis

No fundamental analysis for Shanghai Junshi Biosciences Co. Ltd yet.

Shanghai Junshi Biosciences Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Shanghai Junshi Biosciences Co. Ltd

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneou…

Full company profile